These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 22873183)

  • 1. Maintenance medication for opiate addiction: the foundation of recovery.
    Bart G
    J Addict Dis; 2012; 31(3):207-25. PubMed ID: 22873183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid Maintenance Therapy: A Review of Methadone, Buprenorphine, and Naltrexone Treatments for Opioid Use Disorder.
    Fipps DC; Oesterle TS; Kolla BP
    Semin Neurol; 2024 Aug; 44(4):441-451. PubMed ID: 38848746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.
    Mannelli P; Peindl KS; Lee T; Bhatia KS; Wu LT
    Curr Drug Abuse Rev; 2012 Mar; 5(1):52-63. PubMed ID: 22280332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV; Katz E; Weitz B; Visconti K
    Am J Obstet Gynecol; 2020 Jan; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heroin anticraving medications: a systematic review.
    Fareed A; Vayalapalli S; Casarella J; Amar R; Drexler K
    Am J Drug Alcohol Abuse; 2010 Nov; 36(6):332-41. PubMed ID: 20955107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical treatment of opioid addiction and dependence.
    Ling W; Rawson RA; Compton M
    Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
    [No Abstract]   [Full Text] [Related]  

  • 9. CE: Acute Pain Management for People with Opioid Use Disorder.
    Broglio K; Matzo M
    Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
    Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
    Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence.
    Jackson H; Mandell K; Johnson K; Chatterjee D; Vanness DJ
    Subst Abus; 2015; 36(2):226-31. PubMed ID: 25775099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.
    Connery HS
    Harv Rev Psychiatry; 2015; 23(2):63-75. PubMed ID: 25747920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.
    Bagley SM; Larochelle MR; Xuan Z; Wang N; Patel A; Bernson D; Silverstein M; Hadland SE; Land T; Samet JH; Walley AY
    Ann Emerg Med; 2020 Jan; 75(1):29-38. PubMed ID: 31591014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.
    Sigmon SC; Bisaga A; Nunes EV; O'Connor PG; Kosten T; Woody G
    Am J Drug Alcohol Abuse; 2012 May; 38(3):187-99. PubMed ID: 22404717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder.
    Haffajee RL; Andraka-Christou B; Attermann J; Cupito A; Buche J; Beck AJ
    Subst Abuse Treat Prev Policy; 2020 Sep; 15(1):69. PubMed ID: 32928272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic treatments for opioid dependence: detoxification and maintenance options.
    Kleber HD
    Dialogues Clin Neurosci; 2007; 9(4):455-70. PubMed ID: 18286804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.